Boston Tech Week 2026: From Platform to Pipeline – Five Lessons from the Frontier of Biotech Innovation
The relationship between scientific platform and therapeutic pipeline sits at the heart of modern biotech company-building.
At Boston Tech Week, Fenwick partner Heidi Erlacher brought together Cartography Biosciences CEO Kevin Parker and a16z partner Jorge Conde to candidly explore that relationship, covering everything from the inflection points that force strategic pivots to the role of artificial intelligence in reshaping how companies get built today. Here are the key takeaways.
The Market Decided When It Was Time to Pivot
For companies founded in the early 2020s, the macro environment did a great deal of the decision-making. When investor enthusiasm for platform-stage companies was high, equity capital flowed freely toward early discovery work. That changed around 2022 and 2023, when investors decisively shifted their focus toward pipeline assets with near-term clinical potential. Companies that had been building platforms discovered, sometimes abruptly, that their path to the next financing round ran through a pipeline, not a platform.
One useful framing emerged from the discussion: A platform inside a biotech company has two distinct customer bases. The first is the internal team developing the company's own drugs. The second is pharma, seeking innovative approaches and potential partnership deals. Those customers are funded differently. Equity investors fund the internal pipeline; pharma partnerships fund the platform. When the two funding sources diverged, companies that recognized the split early and went to pharma for platform capital while seeking equity for pipeline development were best positioned to navigate the difficult years that followed.
Platforms Are Only as Valuable as the Problems They Solve
The most productive platform companies share a defining habit: they think forward from the science and backward from the market at the same time. Before committing to a lead program, the strongest founders ask both what their platform can find and whether the world needs it.
That dual orientation, toward unmet clinical need and toward what pharma, investors, and patients will ultimately value, is what distinguishes a pipeline worth building from one that simply optimizes around a platform's existing capabilities. Technology selection and problem selection are two distinct skills, and matching genuinely novel science to the highest-value indications requires deep knowledge of competitive dynamics, standard of care, and commercial reality.
Even programs that do not ultimately succeed contribute to the field's collective knowledge. Work done preclinically or in the clinic, whatever its outcome, informs what researchers and developers do next. Getting something wrong, rigorously and transparently, moves science forward. The strongest founders hold both of these things at once: clear ambition about the problem they are solving and an honest recognition that every well-executed experiment, approved drug or not, is a contribution worth making.
Hiring Is the Real Transition
The operational change most frequently cited as critical to the platform-to-pipeline transition was talent. Academic founders skilled at analysis, genomics, and computational work need a different kind of team to build a drug. Bringing in experienced drug developers (people with track records at major pharmaceutical companies or late-stage biotechs who understand IND-enabling studies, regulatory strategy, and clinical execution) is not a sign of a platform's failure. It is the natural maturation of a company.
The harder challenge is knowing what "great" looks like in those roles before you have ever hired for them. Founders who succeed are the ones who are honest about what they do not know and build around that. Looking at titles rather than substance or failing to recruit people with actual experience navigating specific challenges ahead are among the most common errors. A steep learning curve on the founder's part and a genuine commitment to attracting exceptional talent are, in the end, inseparable from the company's ability to execute.
AI Is a Force Multiplier, Not a Shortcut
Artificial intelligence has not yet produced a development candidate at the push of a button, and it is unlikely to do so soon. That said, its practical impact on biotech company-building has been substantial. Teams are leaner because AI can supply expertise that once required a dedicated headcount. Founders arrive at first investor meetings better informed about their targets, patient populations, and competitive landscapes, because AI compresses research that once took months and significant resources.
Where biotech companies should think carefully is around competitive moat. Proficiency with AI modeling alone is not sufficient differentiation, given how quickly models improve and proliferate. The companies most likely to build durable advantages are those pairing AI with something proprietary: unique patient tissue access, a curated dataset that others cannot replicate, or a therapeutic output that is genuinely novel. The relevant question is whether the advantage persists if the underlying model changes.
Transparency Is the Foundation of Every Good Investor Relationship
The panel was clear that the most productive founder-investor dynamics are built on consistent, honest communication. Investors understand that biotech is extraordinarily hard. They expect setbacks. What unsettles them most is silence, because when founders stop communicating, the natural assumption is that the news is bad. Founders who communicate proactively, set realistic expectations, and deliver on stated commitments build a reservoir of trust that proves invaluable when things do not go according to plan.
The same principle extends to pharma partnership discussions and IP strategy: Build relationships with people you trust, share what is necessary to move the work forward, and use legal protections thoughtfully. Working in near-total secrecy carries its own costs, and disclosing too little to prospective partners can be just as damaging as disclosing too much.
Biotech is in a period of meaningful transition. The companies that will define the next decade are those willing to be honest about what the market requires, clear-eyed about what their science can actually deliver, and disciplined about building the right team at every stage of the journey.